Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Leucine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.75 |
| ▸ | SLC1A3 | P43003 | 7/20 | 0.59 |
| ▸ | SLC1A2 | P43004 | 7/20 | 0.59 |
| ▸ | SLC1A1 | P43005 | 7/20 | 0.50 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.44 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.44 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.44 |
| ▸ | PGR | P06401 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.44 |
| ▸ | GRIK1 | P39086 | 5/20 | 0.42 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.42 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.42 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.42 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.40 |
| ▸ | GRIK3 | Q13003 | 3/20 | 0.40 |
| ▸ | GRIK5 | Q16478 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leucine SCHEMBL5665165 | 1.00 | SLC7A5 (0.75) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| Leucine SCHEMBL4394541 | 1.00 | SLC7A5 (0.75) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| Leucine SCHEMBL782845 | 1.00 | SLC7A5 (0.75) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| Leucine SCHEMBL4664449 | 1.00 | SLC7A5 (0.75) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| Leucine SCHEMBL4946381 | 1.00 | SLC7A5 (0.75) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| Leucine SCHEMBL15322750 | 0.96 | SLC7A5 (0.69) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| Leucine SCHEMBL15322747 | 0.96 | SLC7A5 (0.69) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| D-Leucine SCHEMBL1537345 | 0.96 | SLC7A5 (0.82) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| Leucine SCHEMBL2154089 | 0.96 | SLC7A5 (0.82) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 | |
| Leucine SCHEMBL625031 | 0.96 | SLC7A5 (0.82) | SLC7A5SLC1A3SLC1A2SLC1A1CACNA2D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1054677-B1 | COSMETIC OR DERMATOLOGICAL USE OF 7-HYDROXYLATED STEROIDS ALONE AND/OR IN COMBINATION WITH ELASTIN DERIVED PEPTIDES | CONNECTIVE TISSUE IMAGINEERING (US) | 2008-10-22 | — | — | EP | claimed |
| US-20050164182-A1 | Nucleoside comprising reporter molecule cleavable by hydrolase such as esterases, phosphatases, peptidases, penicillin amidases, glycosidases, and phosphorylases; limits polymerase activity; sequencing; solid phase synthesis | GE HEALTHCARE UK LIMITED (GB) | 2005-07-28 | — | — | US | claimed |
| JP-2005517646-A | — | — | 2005-06-16 | — | — | JP | claimed |
| EP-1064010-A4 | PEPTIDE COMPOSITIONS AND FORMULATIONS AND USE OF SAME | CONNECTIVE TISSUE IMAGINEERING (US) | 2004-10-06 | — | — | EP | claimed |
| EP-1451201-A2 | NUCLEOTIDE ANALOGUES AND THEIR USE FOR NUCLEIC ACID SEQUENCING | Amersham Biosciences UK Limited (GB) | 2004-09-01 | — | — | EP | claimed |
| US-6777389-B1 | INHIBITING CUTANEOUS EFFECTS OF AGING | CONNECTIVE TISSUE IMAGINEERING LLC | 2004-08-17 | — | — | US | claimed |
| WO-2003048178-A2 | NUCLEOTIDE ANALOGUES AND THEIR USE FOR NUCLEIC ACID SEQUENCING | AMERSHAM BIOSCIENCES UK LIMITED (GB) | 2003-06-12 | — | — | WO | claimed |
| CN-1300220-A | Peptide compositions and formulations and use of same | MRS LTD (US) | 2001-06-20 | — | — | CN | claimed |
| EP-1064010-A1 | PEPTIDE COMPOSITIONS AND FORMULATIONS AND USE OF SAME | Mrs, Llc (US) | 2001-01-03 | — | — | EP | claimed |
| WO-1999045941-A1 | PEPTIDE COMPOSITIONS AND FORMULATIONS AND USE OF SAME | MRS, LLC (US) | 1999-09-16 | — | — | WO | claimed |
| CN-107118259-B | Active peptide and whitening cream containing same | 温州千瑞生物科技有限公司 | 2020-08-18 | — | — | CN | disclosed |
| CN-108129551-B | Peptide having skin whitening effect and use thereof | 温州千瑞生物科技有限公司 | 2020-03-31 | — | — | CN | disclosed |
| US-7666842-B2 | Elastin peptide analogs and uses thereof | Connective Tissue Imagineering, LLC (US) | 2010-02-23 | — | — | US | disclosed |
| EP-1054677-B1 | COSMETIC OR DERMATOLOGICAL USE OF 7-HYDROXYLATED STEROIDS ALONE AND/OR IN COMBINATION WITH ELASTIN DERIVED PEPTIDES | CONNECTIVE TISSUE IMAGINEERING (US) | 2008-10-22 | — | — | EP | disclosed |
| EP-1064010-B1 | PEPTIDE COMPOSITIONS AND FORMULATIONS AND USE OF SAME | CONNECTIVE TISSUE IMAGINEERING (US) | 2008-02-20 | — | — | EP | disclosed |
| US-6506731-B1 | Peptide or peptide-like compound(s) of the present invention appear to aid the elasticity and/or turgor of the skin | CONNECTIVE TISSUE IMAGINEERING LLC | 2003-01-14 | — | — | US | disclosed |
| WO-2001091700-A2 | COMPOSITION AND METHOD FOR ENHANCING ELASTICITY OF TISSUE | CONNECTIVE TISSUE IMAGINEERING LLC (US) | 2001-12-06 | — | — | WO | disclosed |
| EP-1054677-A1 | COSMETIC OR DERMATOLOGICAL USE OF 7-HYDROXYLATED STEROIDS ALONE AND/OR IN COMBINATION WITH ELASTIN DERIVED PEPTIDES | Mrs, Llc (US) | 2000-11-29 | — | — | EP | disclosed |
| US-6069129-A | COMPOSITION FOR TREATING MAMMALIAN TISSUE COMPRISING PEPTIDE(S) OF GIVEN SEQUENCES; APPLYING TO HUMAN SKIN IN A COSMETIC OR THERAPEUTIC FORMULATION RESULTING IN ENHANCED ELASTICITY OF THE SKIN | MRS, LLC (US) | 2000-05-30 | — | — | US | disclosed |
| WO-2000028996-A1 | COSMETIC OR DERMATOLOGICAL USE OF 7-HYDROXYLATED STEROIDS ALONE AND/OR IN COMBINATION WITH ELASTIN DERIVED PEPTIDES | MRS, LLC (US) | 2000-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050164182-A1 | Nucleoside comprising reporter molecule cleavable by hydrolase such as esterases, phosphatases, peptidases, penicillin amidases, glycosidases, and phosphorylases; limits polymerase activity; sequencing; solid phase synthesis | PNP, PEPD, DNPEP | SLC7A5 2009/4885SLC1A3 2903/4885SLC1A2 3422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.